boron-conjugated 4-anilinoquinazoline derivative (Mebiopharm)

N/A

Report date: 2026/05/14 13:21:52

Base Information

Drug Nameboron-conjugated 4-anilinoquinazoline derivative (Mebiopharm)
Drug Alias NameEGFR/VEGFR tyrosine kinase inhibitor (Mebiopharm)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsVascular endothelial growth factor receptor inhibitors
TargetsEpidermal growth factor receptor erbB1Vascular endothelial growth factor receptor
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMebiopharm Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMebiopharm Co Ltd
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A